Oncology Central

Indications for transplantation in childhood acute leukemia and the impact of minimal residual disease on relapse: a review


Allogeneic hematopoietic cell transplantation (HCT) for pediatric acute leukemia continues to offer a cure for some patients with high-risk or relapsed disease. Presently, HCT in first remission is recommended only for patients with predicted leukemia-free survival <50%. Despite recent advances, relapse remains the biggest hurdle in HCT.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.